Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Endothelium-derived semaphorin 3G attenuates ischemic retinopathy by coordinating β-catenin–dependent vascular remodeling
Dan-Yang Chen, Ning-He Sun, Xiang Chen, Jun-Jie Gong, Song-Tao Yuan, Zi-Zhong Hu, Nan-Nan Lu, Jakob Körbelin, Kohji Fukunaga, Qing-Huai Liu, Ying-Mei Lu, Feng Han
Dan-Yang Chen, Ning-He Sun, Xiang Chen, Jun-Jie Gong, Song-Tao Yuan, Zi-Zhong Hu, Nan-Nan Lu, Jakob Körbelin, Kohji Fukunaga, Qing-Huai Liu, Ying-Mei Lu, Feng Han
View: Text | PDF
Research Article Vascular biology

Endothelium-derived semaphorin 3G attenuates ischemic retinopathy by coordinating β-catenin–dependent vascular remodeling

  • Text
  • PDF
Abstract

Abnormal angiogenesis and regression of the diseased retinal vasculature are key processes associated with ischemic retinopathies, but the underlying mechanisms that regulate vascular remodeling remain poorly understood. Here, we confirmed the specific expression of semaphorin 3G (Sema3G) in retinal endothelial cells (ECs), which was required for vascular remodeling and the amelioration of ischemic retinopathy. We found that Sema3G was elevated in the vitreous fluid of patients with proliferative diabetic retinopathy (PDR) and in the neovascularization regression phase of oxygen-induced retinopathy (OIR). Endothelial-specific Sema3G knockout mice exhibited decreased vessel density and excessive matrix deposition in the retinal vasculature. Moreover, loss of Sema3G aggravated pathological angiogenesis in mice with OIR. Mechanistically, we demonstrated that HIF-2α directly regulated Sema3G transcription in ECs under hypoxia. Sema3G coordinated the functional interaction between β-catenin and VE-cadherin by increasing β-catenin stability in the endothelium through the neuropilin-2 (Nrp2)/PlexinD1 receptor. Furthermore, Sema3G supplementation enhanced healthy vascular network formation and promoted diseased vasculature regression during blood vessel remodeling. Overall, we deciphered the endothelium-derived Sema3G-dependent events involved in modulating physiological vascular remodeling and regression of pathological blood vessels for reparative vascular regeneration. Our findings shed light on the protective effect of Sema3G in ischemic retinopathies.

Authors

Dan-Yang Chen, Ning-He Sun, Xiang Chen, Jun-Jie Gong, Song-Tao Yuan, Zi-Zhong Hu, Nan-Nan Lu, Jakob Körbelin, Kohji Fukunaga, Qing-Huai Liu, Ying-Mei Lu, Feng Han

×

Figure 13

Supplementation of Sema3G ameliorates ischemic retinopathy in the OIR model.

Options: View larger image (or click on image) Download as PowerPoint
Supplementation of Sema3G ameliorates ischemic retinopathy in the OIR mo...
(A and B) Transduction of ECs with AAV in Sema3Gfl/fl and Cdh5-Cre Sema3Gfl/fl OIR mice. Neonatal mice were injected through the retro-orbital sinus with AAV-Control or AAV-Sema3G at P7 and P12. The retinas were analyzed at P19. (C and D) Immunoblots and quantification analysis showed overexpression of Sema3G in the retinas of AAV-Sema3G–injected mice compared with AAV-Control–injected mice (n = 3 independent experiments). (E) IB4 staining of whole-mount retinas from OIR mice infected with AAV-Control or AAV-Sema3G. (F and G) Quantification of the avascular areas and the NVT area at P19 in OIR, related to E (n = 8, 10, 9, and 9 mice for Sema3Gfl/fl + AAV-Control, Sema3Gfl/fl + AAV-Sema3G, Cdh5-Cre Sema3Gfl/fl + AAV-Control and Cdh5-Cre Sema3Gfl/fl + AAV-Sema3G groups, respectively). (H and I) Schematic illustration of the OIR mice treated with intravitreal injections of recombinant Sema3G. At P15, mouse pups were intravitreally injected with 1 μg IgG or recombinant Sema3G. Retinas were analyzed at P17. (J) Entire eye samples of mice were harvested and homogenized, then prepared for immunoblot analysis of total Sema3G protein abundance. (K) IB4 staining of whole-mount retinas from Sema3Gfl/fl and Cdh5-Cre Sema3Gfl/fl OIR mice injected with IgG or recombinant Sema3G. (L and M) Quantification of the avascular area and NVT area at P17 in OIR, related to K (n = 10, 10, 10, and 10 mice for Sema3Gfl/fl + IgG, Sema3Gfl/fl + Sema3G, Cdh5-Cre Sema3Gfl/fl + IgG and Cdh5-Cre Sema3Gfl/fl + Sema3G groups, respectively). Error bars represent mean ± SEM. **P < 0.01; ***P < 0.001; 1-way ANOVA with Tukey’s multiple comparisons test. Scale bars: 1000 μm (E and K).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts